GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » Shiller PE Ratio

Scorpius Holdings (Scorpius Holdings) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Scorpius Holdings Shiller PE Ratio Historical Data

The historical data trend for Scorpius Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings Shiller PE Ratio Chart

Scorpius Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scorpius Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Scorpius Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Scorpius Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Shiller PE Ratio falls into.



Scorpius Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Scorpius Holdings's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Scorpius Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.16/131.7762*131.7762
=-0.160

Current CPI (Mar. 2024) = 131.7762.

Scorpius Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -30.399 100.560 -39.836
201409 -31.780 100.428 -41.700
201412 -38.689 99.070 -51.462
201503 -39.380 99.621 -52.091
201506 -38.689 100.684 -50.637
201509 -42.834 100.392 -56.225
201512 -53.888 99.792 -71.159
201603 -34.544 100.470 -45.308
201606 -11.745 101.688 -15.220
201609 -5.527 101.861 -7.150
201612 -9.288 101.863 -12.016
201703 -8.260 102.862 -10.582
201706 -6.370 103.349 -8.122
201709 -4.480 104.136 -5.669
201712 -2.940 104.011 -3.725
201803 -4.970 105.290 -6.220
201806 -1.820 106.317 -2.256
201809 -1.120 106.507 -1.386
201812 -1.064 105.998 -1.323
201903 -1.190 107.251 -1.462
201906 -0.980 108.070 -1.195
201909 -1.260 108.329 -1.533
201912 -0.710 108.420 -0.863
202003 -0.770 108.902 -0.932
202006 -0.350 108.767 -0.424
202009 -0.430 109.815 -0.516
202012 -0.210 109.897 -0.252
202103 -0.310 111.754 -0.366
202106 -0.260 114.631 -0.299
202109 -0.300 115.734 -0.342
202112 -0.540 117.630 -0.605
202203 -0.320 121.301 -0.348
202206 -0.270 125.017 -0.285
202209 -0.520 125.227 -0.547
202212 -0.600 125.222 -0.631
202303 -0.490 127.348 -0.507
202306 -0.530 128.729 -0.543
202309 -0.500 129.860 -0.507
202312 -0.210 129.419 -0.214
202403 -0.160 131.776 -0.160

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Scorpius Holdings  (AMEX:SCPX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Scorpius Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Scorpius Holdings (Scorpius Holdings) Business Description

Traded in Other Exchanges
Address
627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560
NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.
Executives
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf director, officer: Chief Executive Officer 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii director C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander officer: CFO/Corp Secy 801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan director
Robert James Jakobs officer: VP Finance/Controller/Secty PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins officer: Chief Scientific Officer 15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar officer: VP of Finance and Controller C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov director 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech officer: Chief Financial Officer C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber officer: Vice President of Research 100 EUROPA DRIVE, CHAPEL HILL NC 27517

Scorpius Holdings (Scorpius Holdings) Headlines

From GuruFocus